To Avoid Bankruptcy, Purdue Pharma Said to Plead Guilty to Illegally Marketing Opioids | News of Interest to Newtown Area Residents | Scoop.it

Purdue Pharma LP has agreed to settle the state of Oklahoma’s claims that its illegal marketing of the Oxycontin painkiller caused financial devastation to local communities, the first accord in a recent wave of lawsuits stemming from the U.S. opioid crisis, according to people familiar with the matter.

 

The settlement comes two months before the scheduled start of a trial against Purdue Pharma, Johnson & Johnson and Teva Pharmaceutical Industries Ltd. in Norman, Oklahoma. Terms of the deal, which covers only Purdue, weren’t immediately available.

 

 Oklahoma claims the three opioid makers understated the risks of prescription painkillers and overstated their benefits, fueling an epidemic that’s costing its communities tens of millions of dollars for treatment and policing. Those companies and others are also battling claims by three dozen other states and 1,600 U.S. cities and counties, but those suits are pending in another court and the first trial isn’t until the fall.

 

The settlement is the first in the most-recent group of opioid lawsuits against Purdue. More than a decade ago, West Virginia settled a case against Purdue over its marketing of Oxycontin, which came on the U.S. market in 1996.

 

Related:

  • “Newtown Township Supervisors Vote to File Civil Lawsuit Against Drug Manufacturers Over Opioid Crisis”; http://sco.lt/7Wibjd
  • “OxyContin Opioid Maker Purdue Pharma Reportedly Exploring Chapter 11 Bankruptcy”; http://sco.lt/8OuLIG
  • “Purdue #Pharma Doesn't Want Court to Unseal Oxycontin Marketing Documents. What's It Hiding?”; http://sco.lt/6wb24f 
  • “OxyContin's 12-hour Problem: Misrepresentation of Efficacy Leads to Addiction & Purdue Knew It”: http://sco.lt/8RfD5F 
  • “The History of Purdue's Marketing of Oxycontin & Its Connection to the Opiate Epidemic”: http://sco.lt/6RajLd
  • “Doctor with Ties to Purdue #Pharma Helped Develop Canadian Opioid-Prescribing Guidelines”: http://sco.lt/7f1iin